Yahoo
NasdaqGM - Nasdaq Real Time Price USD

PROCEPT BioRobotics Corporation (PRCT)

19.20 -1.10 (-5.42%)
At close: October 30 at 4:00:00 PM EDT
19.20 0.00 (0.00%)
After hours: October 30 at 4:00:16 PM EDT
Trade PRCT on Coinbase
Chart Range Bar
Loading chart for PRCT
  • Previous Close 20.30
  • Open 20.33
  • Bid 13.90 x 200
  • Ask 22.04 x 200
  • Day's Range 18.90 - 20.37
  • 52 Week Range 16.67 - 38.11
  • Volume 856,458
  • Avg. Volume 1,346,760
  • Market Cap (intraday) 1.093B
  • Beta (5Y Monthly) 0.92
  • PE Ratio (TTM) --
  • EPS (TTM) -1.94
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 22.25
  • Motley Fool Rating Bullish

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

www.procept-biorobotics.com

888

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PRCT
38.97%
S&P 500 (^GSPC)
10.73%

1-Year Return

PRCT
44.15%
S&P 500 (^GSPC)
11.11%

3-Year Return

PRCT
22.86%
S&P 500 (^GSPC)
81.91%

5-Year Return

PRCT
55.07%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 94.5M
Earnings -26.86M
Profit Margin -28.42%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-20M
0
20M
40M
60M
80M
-35.0%
-30.0%

Analyst Insights

View More

Analyst Price Targets

16.00 Low
22.25 Average
19.20 Current
30.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/7/2026
Analyst Barclays
Rating Action Initiated
Rating Overweight
Price Action Announces
Price Target 30

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -32.53%

  • Return on Assets (ttm)

    -14.75%

  • Return on Equity (ttm)

    -30.24%

  • Revenue (ttm)

    337.34M

  • Net Income Avi to Common (ttm)

    -109.75M

  • Diluted EPS (ttm)

    -1.94

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    227.91M

  • Total Debt/Equity (mrq)

    22.79%

  • Levered Free Cash Flow (ttm)

    -48.97M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: